Maccura Biotechnology faces challenges in PCR product line

Maccura Biotechnology (SZSE:300463) is facing headwinds in its digital PCR product line, leading to a significant impairment. According to a continuous supervision report by China Merchants Securities, Maccura recognized a CNY 94 million impairment loss on the goodwill associated with its digital PCR assets in 2024. This write-down is a primary factor in the company's 59.44% decline in net profit for the year. The challenges stem from a slowing market for digital PCR products, saturation of demand from universities and research institutions, and budget cuts among IVD and CRO companies. Additionally, a delay in launching an updated product model (D610) further hampered sales. While the company has engaged an appraisal firm and recognized the impairment, ongoing scrutiny of Maccura's financial performance and market conditions is advised, says China Merchants Securities.